Avalyn Pharma Inc. (AVLN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$92.3M
Cash & Equivalents
$29.9M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$1,244M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06329401 | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | PHASE2 | Active Not Recruiting | 375 |
| NCT07194382 | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | PHASE2 | Recruiting | 160 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-17 | 8-K | Avalyn Pharma Inc. (AVLN) (CIK 0001540171) - EX-99.1 | EDGAR |